Press monitoring
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
11.2.2016 | Press monitoring
Holzkirchen, 11 February, 2016 - Sandoz, a Novartis company and the global leader in biosimilars, announced today that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for its biosimilar to Amgen's EU-licensed Neulasta ®* (pegfilgrastim) - a long-acting recombinant human granulocyte...
From allergens to anodes: Pollen derived battery electrodes
10.2.2016 | Press monitoring
Pollens, the bane of allergy sufferers, could represent a boon for battery makers: Recent research has suggested their potential use as anodes in lithium-ion batteries. "Our findings have demonstrated that renewable pollens could produce carbon architectures for anode applications in energy storage devices," said Vilas Pol, an associate...
First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic Aneurysm Study
9.2.2016 | Press monitoring
DUBLIN and SIOUX FALLS, S.D. - February 9, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions and Sanford Health, one of the nation's largest health care systems, today announced the first patient enrolled in a clinical study using the Medtronic Valiant® TAAA Stent Graft System for minimally invasive...
Researchers sequence bedbug genome, find unique features
8.2.2016 | Press monitoring
Purdue University researchers participated in a multi-institute project that sequenced the genome of the common bedbug, a blood-sucking insect that has reemerged globally as a hardy pest capable of withstanding most major classes of insecticides. The genome of Cimex lectularius uncovers the genetic underpinning of bedbugs' unique biology and...
Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
5.2.2016 | Press monitoring
DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure. The Medtronic Amplia MRI(TM) Quad CRT-D SureScan®...
New detection method for Goby fish invasion
5.2.2016 | Press monitoring
Ponto-Caspian gobies are a flock of five invasive fish species that have colonized freshwaters and brackish waters in Europe and North America. One of them, the round goby Neogobius melanostomus, figures among the 100 worst invaders in Europe. Current methods to detect the presence of Ponto-Caspian gobies involve catching or sighting the fish....
Biologist\'s gene-editing kit lets do-it-yourselfers play God at the kitchen table
3.2.2016 | Press monitoring
On the kitchen table of his cramped apartment, Josiah Zayner is performing the feat that is transforming biology. In tiny vials, he's cutting, pasting and stirring genes, as simply as mixing a vodka tonic. Next, he slides his new hybrid creations, living in petri dishes, onto a refrigerator shelf next to the vegetables. And he's packaging and...
Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine
2.2.2016 | Press monitoring
Lyon, France - February 2, 2016 - Sanofi Pasteur , the vaccines division of Sanofi , announced today that it has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
VALNEVA Evaluating Development of Zika Vaccine as Virus Spreads Through the Americas
2.2.2016 | Press monitoring
Lyon (France), February 2, 2016 - Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announces today that it is evaluating the development of a Zika vaccine as the virus is spreading rapidly through the Americas.
LivaNova PLC Announces FDA Approval of Stented Heart Valve CROWN PRT(TM) for Aortic Valve Disease
1.2.2016 | Press monitoring
LONDON, Feb. 01, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (the "Company"), a global medical technology company and a leader in the treatment of cardiovascular diseases, today announced it has been granted approval from the United States Food and Drug Administration (FDA) for its innovative stented aortic bioprosthesis...
